|
1
|
Kanguru L, Bikker A, Cavers D, Barnett K,
Brewster DH, Weller D and Campbell C: Pathways to diagnosis of a
second primary cancer: Protocol for a mixed-methods systematic
review. BMJ Open. 7:e0179292017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Spratt JS Jr and Hoag MG: Incidence of
multiple primary cancers per man-year of follow up: 20-year review
from the Ellis Fischel State Cancer Hospital. Ann Surg.
164:775–784. 1966. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Demandante CG, Troyer DA and Miles TP:
Multiple primary malignant neoplasms: Case report and a
comprehensive review of the literature. Am J Clin Oncol. 26:79–83.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hayat MJ, Howlader N, Reichman ME and
Edwards BK: Cancer statistics, trends, and multiple primary cancer
analyses from the surveillance, epidemiology, and end results
(SEER) program. Oncologist. 12:20–37. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Coyte A, Morrison DS and McLoone P: Second
primary cancer risk-the impact of applying different definitions of
multiple primaries: Results from a retrospective population-based
cancer registry study. BMC cancer. 14:2722014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Utada M, Ohno Y, Hori M and Soda M:
Incidence of multiple primary cancers and interval between first
and second primary cancers. Cancer Sci. 105:890–896. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Molina-Montes E, Requena M,
Sánchez-Cantalejo E, Fernández MF, Arroyo-Morales M, Espín J,
Arrebola JP and Sánchez MJ: Risk of second cancers cancer after a
first primary breast cancer: A systematic review and meta-analysis.
Gynecol Oncol. 136:158–171. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Travis LB: Therapy-associated solid
tumors. Acta Oncol. 41:323–333. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Travis LB, Fosså SD, Schonfeld SJ,
McMaster ML, Lynch CF, Storm H, Hall P, Holowaty E, Andersen A,
Pukkala E, et al: Second cancers among 40,576 testicular cancer
patients: Focus on long-term survivors. J Natl Cancer Inst.
97:1354–1365. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Travis LB, Rabkin CS, Brown LM, Allan JM,
Alter BP, Ambrosone CB, Begg CB, Caporaso N, Chanock S, DeMichele
A, et al: Cancer survivorship-genetic susceptibility and second
primary cancers: Research strategies and recommendations. J Natl
Cancer Inst. 98:15–25. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kaneko S and Yamaguchi N: Epidemiological
analysis of site relationships of synchronous and metachronous
multiple primary cancers in the National Cancer Center, Japan,
1962–1996. Jpn J Clin Oncol. 29:96–105. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sobin LH, Gospodarowicz MK and Wittekind
C; and International Union against Cancer, : TNM classification of
malignant tumours. Wiley-Blackwell; Chichester, West Sussex, UK;
Hoboken, NJ: 2010
|
|
13
|
National Cancer Institute (U.S.): Common
terminology criteria for adverse events (CTCAE), . U.S. Dept. of
Health and Human Services. National Institutes of Health, National
Cancer Institute; Bethesda, Md.: 2009
|
|
14
|
Warren S and Gates O: Multiple primary
malignant tumors: A survey of the literature and statistical study.
Am J Cancer. 16:1358–1414. 1932.
|
|
15
|
Németh Z, Czigner J, Iván L, Ujpál M,
Barabás J and Szabó G: Quadruple cancer, including triple cancers
in the head and neck region. Neoplasma. 49:412–414. 2002.PubMed/NCBI
|
|
16
|
Moertel CG, Dockerty MB and Baggenstoss
AH: Multiple primary malignant neoplasms. I. Introduction and
presentation of data. Cancer. 14:221–230. 1961. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vogt A, Schmid S, Heinimann K, Frick H,
Herrmann C, Cerny T and Omlin A: Multiple primary tumours:
Challenges and approaches, a review. ESMO Open. 2:e0001722017.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bartelink H, Roelofsen F, Eschwege F,
Rougier P, Bosset JF, Gonzalez DG, Peiffert D, van Glabbeke M and
Pierart M: Concomitant radiotherapy and chemotherapy is superior to
radiotherapy alone in the treatment of locally advanced anal
cancer: Results of a phase III randomized trial of the European
Organization for Research and Treatment of Cancer Radiotherapy and
Gastrointestinal Cooperative Groups. J Clin Oncol. 15:2040–2049.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Huang K, Haas-Kogan D, Weinberg V and
Krieg R: Higher radiation dose with a shorter treatment duration
improves outcome for locally advanced carcinoma of anal canal.
World J Gastroenterol. 13:895–900. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Peiffert D, Tournier-Rangeard L, Gérard
JP, Lemanski C, François E, Giovannini M, Cvitkovic F, Mirabel X,
Bouché O, Luporsi E, et al: Induction chemotherapy and dose
intensification of the radiation boost in locally advanced anal
canal carcinoma: Final analysis of the randomized UNICANCER ACCORD
03 trial. J Clin Oncol. 30:1941–1948. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Landoni F, Maneo A, Colombo A, Placa F,
Milani R, Perego P, Favini G, Ferri L and Mangioni C: Randomised
study of radical surgery versus radiotherapy for stage Ib-IIa
cervical cancer. Lancet. 350:535–540. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Toita T, Kato S, Niibe Y, Ohno T, Kazumoto
T, Kodaira T, Kataoka M, Shikama N, Kenjo M, Tokumaru S, et al:
Prospective multi-institutional study of definitive radiotherapy
with high-dose-rate intracavitary brachytherapy in patients with
nonbulky (<4-cm) stage I and II uterine cervical cancer
(JAROG0401/JROSG04-2). Int J Radiat Oncol Biol Phys. 82:e49–e56.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Brierley J, Gospodarowicz MK and Wittekind
C: TNM classification of malignant tumours. Wiley Blackwell;
Chichester, West Sussex, UK; Hoboken, NJ: 2017
|
|
24
|
Ajani JA, Winter KA, Gunderson LL,
Pedersen J, Benson AB III, Thomas CR Jr, Mayer RJ, Haddock MG, Rich
TA and Willett C: Fluorouracil, mitomycin, and radiotherapy vs
fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal
canal: A randomized controlled trial. JAMA. 299:1914–1921. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kachnic LA, Winter K, Myerson RJ, Goodyear
MD, Willins J, Esthappan J, Haddock MG, Rotman M, Parikh PJ, Safran
H and Willett CG: RTOG 0529: A phase 2 evaluation of dose-painted
intensity modulated radiation therapy in combination with
5-fluorouracil and mitomycin-C for the reduction of acute morbidity
in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys.
86:27–33. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jadon R, Pembroke CA, Hanna CL,
Palaniappan N, Evans M, Cleves AE and Staffurth J: A systematic
review of organ motion and image-guided strategies in external beam
radiotherapy for cervical cancer. Clin Oncol (R Coll Radiol).
26:185–196. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Taylor A and Powell ME: An assessment of
interfractional uterine and cervical motion: Implications for
radiotherapy target volume definition in gynaecological cancer.
Radiother Oncol. 88:250–257. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zeng L, Ou G, Itasaka S, Harada H, Xie X,
Shibuya K, Kizaka-Kondoh S, Morinibu A, Shinomiya K and Hiraoka M:
TS-1 enhances the effect of radiotherapy by suppressing
radiation-induced hypoxia-inducible factor-1 activation and
inducing endothelial cell apoptosis. Cancer Sci. 99:2327–2335.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Boku N, Yamamoto S, Fukuda H, Shirao K,
Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Takiuchi H, et
al: Fluorouracil versus combination of irinotecan plus cisplatin
versus S-1 in metastatic gastric cancer: A randomised phase 3
study. Lancet Oncol. 10:1063–1069. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Takashima A, Shimada Y, Hamaguchi T, Ito
Y, Nakano A, Nakamura K, Shibata T, Fukuda H and Moriya Y:
Colorectal Cancer Study Group of the Japan Clinical Oncology Group:
A Phase I/II trial of chemoradiotherapy concurrent with S-1 plus
mitomycin C in patients with clinical Stage II/III squamous cell
carcinoma of anal canal (JCOG0903: SMART-AC). Jpn J Clin Oncol.
41:713–717. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li Z, Mao W, Lin N and Han S: Concurrent
radiotherapy with S-1 plus cisplatin versus concurrent radiotherapy
with cisplatin alone for the treatment of locally advanced cervical
carcinoma: A pilot randomised controlled trial. Clin Transl Oncol.
18:413–417. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Schwarz JK, Lewis JS Jr, Pfeifer J,
Huettner P and Grigsby P: Prognostic significance of p16 expression
in advanced cervical cancer treated with definitive radiotherapy.
Int J Radiat Oncol Biol Physics. 84:153–157. 2012. View Article : Google Scholar
|
|
33
|
Serup-Hansen E, Linnemann D,
Skovrider-Ruminski W, Høgdall E, Geertsen PF and Havsteen H: Human
papillomavirus genotyping and p16 expression as prognostic factors
for patients with American Joint Committee on Cancer stages I to
III carcinoma of the anal canal. J Clin Oncol. 32:1812–1817. 2014.
View Article : Google Scholar : PubMed/NCBI
|
